The State Food and Drug Administration approved the import registration of Monoravir capsules, Merck's new coronavirus treatment drug

According to the official website of the State Food and Drug Administration, on December 29, in accordance with the relevant provisions of the Drug Administration Law, the State Food and Drug Administration conducted emergency review and approval in accordance with the special approval procedures for drugs, and conditionally approved the import registration
of Merck's new coronavirus treatment drug monogravir capsules (trade name: Lizhuorui/LAGEVRIO).

This product is an oral small molecule new coronavirus treatment drug, which is used to treat adult patients with mild to moderate novel coronavirus infection (COVID-19) with risk factors for progression to severe disease, such as patients with advanced age, obesity or overweight, chronic kidney disease, diabetes, severe cardiovascular disease, chronic obstructive pulmonary disease, active cancer and other high-risk factors for severe disease
.
Patients should take the drug strictly according to the instructions under the
guidance of a physician.
(Zhongxin Finance)